Upload
shon-gardner
View
228
Download
3
Tags:
Embed Size (px)
Citation preview
RESPIRATORY RESPIRATORY PAEDIATRICSPAEDIATRICSRESPIRATORY RESPIRATORY PAEDIATRICSPAEDIATRICS
Dr Pamela LewisDr Pamela Lewis
The Respiratory History• History of presenting complaint• Nature of symptoms• Chronic symptoms• Risk Factors• Associated symptoms• Growth• Impact
Respiratory Risk Factors
• Prematurity• Chronic lung disease• Smoking• Atopy• Family history• Immunodeficiency• Social
Respiratory Examination
• Observe• Respiratory rate• Clubbing• HR• Cyanosis• Chest Shape• Expansion• Percussion• Auscultation
Bronchiolitis• Viral infection of the small airways• Respiratory Syncitial Virus• Infants• Symptoms • Signs• Management• Prevention
Bronchiolitis Presentation
• Cough, respiratory distress, poor feeding• Tachypnoea, recession, crackles and
wheeze• Supportive management:
Oxygen, fluids no proven role for bronchodilators or steroids, limited evidence for ribavarin, ventilatory support
Bronchiolitis Prevention• Palivizumab
monoclonal antibody, monthly injections to at risk population
• Vaccine? Not currently
Croup Presentation and Management
• Barking cough, respiratory distress poor feeding
• Stridor, tracheal tug, recession, not toxic• Limit anxiety and call for assistance if
severe• Steroids oral dexamethasone• Consider nebulised adrenaline• Airway support if necessary
Epiglottitis• Severe upper airway infection• Haemophilus influenzae• Presentation• Management• Prevention
Epiglottitis Presentation and
Management• Toxic, drooling stridor and respiratory
distress• Medical Emergency• Call for HELP• Keep child calm• Rapid Sequence induction of
anaesthesia• IV Ceftriaxone• Hib Vaccine
Asthma• Common 1.1 million children in uk
receiving treatment for asthma• Inflamatory condition of the
bronchial airways resulting in increased mucus production, mucosal swelling and muscle contraction. Reversible
Diagnosis of Asthma in Children
• Presence of key features• Assessment of trials of treatment• Repeated reassessment and
question diagnosis if not responding
• Pulmonary function tests (if age appropriate)
Key Features in Asthma• Symptoms: cough, wheeze,
SOB,chest tightness, exertional symptoms
• Risk Factors: atopy, FH, smoking, preterm
• Signs: None, hyperexpansion, Harrisons sulci
PFT in Diagnosis of asthma
• Depends on age• >20% diurnal variation in PEF on
>3 days/wk for 2 weeks• FEV1 > 15% after salbutamol• FEV1> 15% drop after 6mins
running• Bronchial hyperreactivity
Differential Diagnosis in Asthma
• Viral wheezing• GOR• Suppurative lung disease• Congenital structural leision• Immunodeficiency• Cardiac
Secondary Prevention• Allergen avoidance• House Dust Mite eradication• Smoking• Pollution• Dietary• Homeopathy
British Thoracic Society Management
• Aims of treatment Early control maintain control with stepwise approach
• Assessment Minimal symptoms day and night No exacerbations No reduction in exercise capability normal lung function
BTS Asthma Management
• STEP 1• Mild intermittent symptoms• Use beta 2 Agonist as required• Move to step 2 if needed >3x/week
or night symptoms>1x/week or if exacerbation in last 2 years
BTS Asthma Management
• Step 2• Regular preventer therapy• Inhaled beta 2 agonist prn and
regular standard dose inhaled corticosteroid
BTS Asthma Management
• Step 3• Add on Treatment• Beta 2 agonist as required and regular
standard dose inhaled corticosteroid and if >5yrs regular long acting beta 2 agonist, if not controlled increase inh steroid dose to top of standard range and if still uncontrolled add in leukotriene antagonist or oral theophyline
BTS Asthma Management
• Step 4• If under 5yrs child should be refered to
a respiratory paediatrician• If >5yrs inhaled beta 2 agonist as
needed and high dose inhaled steroids and regular long acting beta 2 agonist and leukotriene antagonist or theophyline
BTS Asthma Management
• Step 5• Refer to respiratory paediatrician• As for step 4 and consider regular
steroid tablets or immunosuppressants
Acute AsthmaSeverity Assessment
• Mild: cough and wheeze, no distress , able to speak and feed, sats >92%
• Moderate: cough, wheeze, use of accessory muscles, sats>92%, feeding, able to speak but breathless.PF>50% if over 5yrs and able to perform
• Severe: sats <92%, toobreathless to talk or feed, tachypnoea and use of accessory muscles, tachycardia nb the silent chest
Acute Asthma• Oxygen• Beta 2 Agonist (salbutamol) neb repeat
as required• Ipratropium nebs• Steroids prednisolone or iv
hydrocortisone• IV salbutamol/ aminophyline• IV magnesium
Drugs in Asthma• Beta 2 Agonists eg salbutamol, terbutaline,
can be administered as inhalor or nebulised (BLUE)
• Long acting beta 2 agonists inhalors (GREEN)• Steroids inhaled eg beclomethasone
(BROWN), Fluticasone(ORANGE). Oral Prednisolone. IV Hydrocortisone
• Leukotriene antagonists eg montelukast tablets or sprinkles
CYSTIC FIBROSIS• 7500 cases in uk• 1:25 carrier rate• Autosomal recessive, chromosome 7• Commonest deletion in UK delta 508
affecting the CFTR protein which codes for chloride channel
• Average life expectancy 30-40
CYSTIC FIBROSIS• Multisystem disease• Respiratory; recurrent resp infections
with resultant bronchiectasis• GIT; pancreatic insufficiency, meconium
ileus equivalent• Hepatic; CF liver disease• Endocrine; diabetes, infertility
CYSTIC FIBROSIS MANAGEMENT
• Multidisciplinary team approach• Physiotherapy• Dietetics• Therapeutic• psychological